- Home
- CSTL vs GPRE Comparison
CSTL vs GPRE Comparison
Compare CSTL & GPRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GPRE
- Stock Information
- Founded
- CSTL 2007
- GPRE 2004
- Country
- CSTL United States
- GPRE United States
- Employees
- CSTL N/A
- GPRE N/A
- Industry
- CSTL Medical Specialities
- GPRE Major Chemicals
- Sector
- CSTL Health Care
- GPRE Industrials
- Exchange
- CSTL Nasdaq
- GPRE Nasdaq
- Market Cap
- CSTL 661.7M
- GPRE 631.4M
- IPO Year
- CSTL 2019
- GPRE N/A
- Fundamental
- Price
- CSTL $33.02
- GPRE $10.12
- Analyst Decision
- CSTL Strong Buy
- GPRE Hold
- Analyst Count
- CSTL 6
- GPRE 8
- Target Price
- CSTL $38.67
- GPRE $8.69
- AVG Volume (30 Days)
- CSTL 421.5K
- GPRE 2.9M
- Earning Date
- CSTL 11-03-2025
- GPRE 11-05-2025
- Dividend Yield
- CSTL N/A
- GPRE N/A
- EPS Growth
- CSTL N/A
- GPRE N/A
- EPS
- CSTL N/A
- GPRE N/A
- Revenue
- CSTL $343,530,000.00
- GPRE $2,246,853,000.00
- Revenue This Year
- CSTL N/A
- GPRE N/A
- Revenue Next Year
- CSTL N/A
- GPRE N/A
- P/E Ratio
- CSTL N/A
- GPRE N/A
- Revenue Growth
- CSTL 10.15
- GPRE N/A
- 52 Week Low
- CSTL $14.59
- GPRE $3.14
- 52 Week High
- CSTL $34.64
- GPRE $12.31
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- GPRE 48.87
- Support Level
- CSTL $23.31
- GPRE $9.98
- Resistance Level
- CSTL $34.36
- GPRE $11.87
- Average True Range (ATR)
- CSTL 1.50
- GPRE 0.71
- MACD
- CSTL 1.08
- GPRE -0.09
- Stochastic Oscillator
- CSTL 89.19
- GPRE 32.96
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.